Regeneron Pharmaceuticals Inc. buy Sanford C. Bernstein
Summary
This prediction is currently active. The BUY prediction by Sanford_C__Bernstein currently has a performance of 11.72%. This prediction currently runs until 12.03.25. The prediction end date can be changed by Sanford_C__Bernstein at any time. Sanford_C__Bernstein has 50% into this predictionRegeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Performance without dividends (%)
Name | 1w | 1m |
---|---|---|
Regeneron Pharmaceuticals Inc. | -0.242% | -0.242% |
iShares Core DAX® | -3.935% | -2.628% |
iShares Nasdaq 100 | -3.608% | -9.283% |
iShares Nikkei 225® | -4.513% | -6.951% |
iShares S&P 500 | -2.607% | -4.402% |
Comments by Sanford_C__Bernstein for this prediction
In the thread Regeneron Pharmaceuticals Inc. diskutieren